Pharmacologic treatment for right ventricular failure
OwnerEmily Joy Tsai, Christos Tzimasinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure provides, inter alia, methods for treating or ameliorating the effect of a cardiopulmonary disease, including right ventricular failure (RVF), in a subject. Also provided are methods for diagnosing the risk of having RVF in a subject, methods for preventing RVF in a subject, methods for preventing non-canonical autophagy, methods for mitigating oxidative stress in mitochondria of a cell, and methods for inhibiting microtubule-mediated active mRNA transfer in a cell. A pharmaceutical composition and treatment methods using such composition are also provided.
Claims21
A method for treating or ameliorating the effect of a cardiopulmonary disease in a subject, comprising modulating the expression of at least one gene of a gene module associated with right ventricular failure (RVF) in the subject.
A method for diagnosing right ventricular failure (RVF) in a subject, comprising:
- (a) obtaining a biological sample from the subject;
- (b) determining the expression level of at least one gene of a gene module in the sample and comparing it to a reference determined in a healthy subject;
- (c) diagnosing the subject as being at risk for right ventricular failure (RVF) if the expression level of the at least one gene of the gene module in the sample is significantly higher than the reference;
- and
- (d) initiating a treatment protocol for the subject diagnosed in step (c) as being at risk for RVF.
A method for preventing right ventricular failure (RVF) in a subject, comprising decreasing the expression of WIPI1, in the subject.
A method for preventing non-canonical autophagy in a cardiac myocyte, comprising decreasing the expression of WIPI1, in the cardiac myocyte.
A method for mitigating oxidative stress in mitochondria of a cardiac myocyte, comprising decreasing the expression of WIPI1, in the cardiac myocyte.
A pharmaceutical composition comprising:
- a first vector expressing CRISPR associated protein 9 (CAS9), a second vector expressing WIPI1 gRNA, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.